ReviewCureus2025
Decoding Autoimmunity: Insights Into Neuromyelitis Optica and Its Relationship With Other Autoimmune Neurological Disorders.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The IL-1β-STING Signaling Axis Drives Neuromyelitis Optica Pathogenesis in a Murine Model.Annals of neurology · 2026Article
- Longitudinally Extensive Transverse Myelitis in Autoimmune Connective Tissue Diseases: A Comprehensive Review.Cureus · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuromyelitis optica (NMO) is a rare but debilitating autoimmune condition characterized by severe attacks of optic neuritis and transverse myelitis, often resulting in significant neurological disability. Autoantibodies targeting aquaporin-4 (AQP4) and myelin oligodendrocyte glycoprotein (MOG) play critical roles in disease pathogenesis, and therapeutic strategies encompassing immunosuppressive therapies and emerging biologics are employed to manage disease activity and prevent relapse. While studies suggest a potential overlap between NMO and other autoimmune neurological conditions, research in this area remains limited. This review explores the commonalities and distinctions between NMO and related autoimmune neurological disorders, hypothesizing that shared autoantibody mechanisms and clinical features may refine diagnostic criteria and therapeutic interventions. Additionally, it addresses tailored management approaches for specific clinical features of NMO and its overlaps. The paper also explores current research on biomarkers and novel treatment modalities, highlighting persistent knowledge gaps, such as understanding the immune mechanisms behind NMO and predicting individual responses to therapies. The review underscores the necessity for collaborative research efforts to improve diagnostic accuracy and therapeutic efficacy. Ultimately, these efforts will enhance personalized care strategies and optimize outcomes and quality of life for patients with NMO and related autoimmune neurological disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.